Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 9/20 | 0.78 |
| ▸ | VIPR2 | P41587 | 10/20 | 0.75 |
| ▸ | GLP1R | P43220 | 5/20 | 0.71 |
| ▸ | ECE1 | P42892 | 1/20 | 0.71 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.71 |
| ▸ | CCKBR | P32239 | 1/20 | 0.68 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 2/20 | 0.66 |
| ▸ | NPY4R | P50391 | 2/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331434 | 0.93 | NPY2R (0.75) | VIPR1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL15669203 | 0.92 | NPY2R (0.74) | VIPR1GLP1RNPY2RNPY4RNPY5R | |
| SCHEMBL29569801 | 0.91 | VIPR1 (0.79) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL29389724 | 0.91 | VIPR1 (0.79) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL31060733 | 0.90 | VIPR1 (0.76) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL29382043 | 0.90 | GLP1R (0.80) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL29523535 | 0.90 | VIPR1 (0.69) | VIPR1VIPR2GLP1RECE1MUS81 | |
| Aviptadil SCHEMBL29357337 | 0.89 | VIPR1 (0.84) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL31060658 | 0.89 | GLP1R (0.89) | VIPR1GLP1RECE1MUS81CCKBR | |
| Glp-1 SCHEMBL29353361 | 0.89 | GLP1R (0.89) | VIPR1GLP1RECE1MUS81CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238382-A1 | URI Agonist/Vasodilator | LILLY CO ELI (US) | 2024-07-18 | — | — | US | disclosed |
| US-11872266-B2 | Rapid-acting insulin compositions | ELI LILLY AND COMPANY (US) | 2024-01-16 | — | — | US | disclosed |
| CN-110662551-B | Quick acting insulin compositions | 伊莱利利公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4169505-A1 | RAPID-ACTING INSULIN COMPOSITIONS | Eli Lilly and Company (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115697379-A | Quick-acting insulin composition and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4108253-A1 | RAPID-ACTING INSULIN COMPOSITIONS | Eli Lilly and Company (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3233108-B1 | RAPID-ACTING INSULIN COMPOSITIONS | LILLY CO ELI (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220072105-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| EP-3943155-A1 | RAPID-ACTING INSULIN COMPOSITIONS | Eli Lilly and Company (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2022002008-A1 | QUICK-ACTING INSULIN COMPOSITION AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-20160166695-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY | 2016-06-16 | — | — | US | disclosed |
| US-20160129087-A1 | RAPID-ACTING INSULIN COMPOSITIONS | LILLY CO ELI (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2015171484-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| EP-2914252-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | Pharnext (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20150231123-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-08-20 | — | — | US | disclosed |
| WO-2015063140-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014068007-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2014-05-08 | — | — | WO | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238382-A1 | URI Agonist/Vasodilator | GPR119, INSR, IAPP | VIPR1 204/4885VIPR2 214/4885GLP1R 5/4885 |
| US-20160166695-A1 | RAPID-ACTING INSULIN COMPOSITIONS | INSR, IAPP, GPR119 | VIPR1 1150/4885VIPR2 1456/4885GLP1R 8/4885 |
| US-20160129087-A1 | RAPID-ACTING INSULIN COMPOSITIONS | INSR, IAPP, GPR119 | VIPR1 278/4885VIPR2 422/4885GLP1R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.